z-logo
Premium
Changes in cerebral blood flow after acetazolamide: an experimental study comparing near‐infrared spectroscopy and SPECT
Author(s) -
Schytz H. W.,
Wienecke T.,
Jensen L. T.,
Selb J.,
Boas D. A.,
Ashina M.
Publication year - 2009
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2008.02398.x
Subject(s) - acetazolamide , cerebral blood flow , medicine , nuclear medicine , indocyanine green , blood flow , bolus (digestion) , single photon emission computed tomography , anesthesia , surgery
Background and purpose:  It is important to find a reliable and bedside method, which can estimate the cerebral blood flow (CBF) of patients in clinical settings. Estimation of CBF by calculating a blood flow index (BFI) using continuous wave near‐infrared spectroscopy (CW‐NIRS) and indocyanine green (ICG) as an iv tracer has been proposed to be a feasible and promising method. To validate if the BFI method can detect relative changes in CBF we compared data with the established method 133 Xenon single photon emission computer tomography ( 133 Xe‐SPECT). Methods:  Ten healthy subjects were investigated before and after a bolus of acetazolamide. NIRS data were obtained using a multi source detector separation configuration in order to assess a corrected BFI (BFI corr ) value, which attempts to eliminate contamination of skin blood flow. Results:  Data obtained showed no significant correlation between CBF changes measured by 133 Xe‐SPECT and BFI corr (0.133, P  =   0.732). After acetazolamide, a 49% increase in CBF was detected using the 133 Xe‐SPECT method, whereas no changes in any ICG variables were observed after acetazolamide. Conclusion:  The study shows that it is not possible to obtain reliable BFI data, which reflect changes in CBF after acetazolamide infusion, using the CW‐NIRS and ICG method.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here